STOCK TITAN

Verrica Pharmaceuticals Inc - VRCA STOCK NEWS

Welcome to our dedicated news page for Verrica Pharmaceuticals (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verrica Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verrica Pharmaceuticals's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.88%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
Verrica Pharmaceuticals Inc

Nasdaq:VRCA

VRCA Rankings

VRCA Stock Data

291.42M
15.07M
39.7%
42.59%
9.87%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
West Chester

About VRCA

verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.